NASDAQ
15.34USD
-0.02 (-0.13%)
We have scored 64 news catalysts on Erasca, Inc. (ERAS) over the past 12 months. The biggest single-day move next to one of them came Jun 22, 2026, when ERAS closed +10.3%: “Sportradar Group AG (SRAD) Facing Securities Class Action Amid Activist Short Seller Accusations of Illegal Business Model and $800 Million Market Cap Wipeout – Hagens Berman”. Coverage across the window leans negative (average ticker sentiment −0.77). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.3B
P/E
—
EPS
—
Beta
0.65
52W range
1.67-24.28
Day range
14.92–16.32
Open
15.83
Prev close
15.36
Volume
7.5M
Avg volume
4.6M
Dividend
0.00
IPO
2021-07-16
Analysts publish price targets on ERAS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $16 to $26
as of 2026-09-04
The market is 23% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Erasca, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ERAS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
The price sits at the 14th percentile of the published model spread, 23% below the median target, meaning the market has largely dismissed the bull case and is pricing in severe setbacks for the lead drug candidate.
What the disagreement turns on
Whether ERAS-0015 can survive its Phase 1 safety failure and intellectual property disputes to retain commercial value; the wired data cannot settle this, as clinical trial outcomes and patent litigation are outside the scope of measurable consumer or volume metrics.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $16.26 on 2026-09-04 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
